Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024. In the quarter to June 2025, revenue fell 89.3%, EPS fell 140.7% and free cash flow fell 174.7%, each against the same quarter a year earlier.
Follow ADAPY
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Older periods | Dec '24 | Mar '25 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
(77.92) | (77.00) | (176.86) | (159.24) |
Depreciation & Amortization |
15.99 | 15.63 | 15.39 | — | |
Non Cash Items (Other) |
21.34 | 17.85 | 16.14 | — | |
Accounts Receivable Change |
(4.00) | (21.20) | (33.95) | — | |
Change in inventories |
— | — | (11.40) | — | |
Accounts Payable Change |
9.94 | 4.58 | (2.48) | — | |
Change in other assets and liabilities |
(69.49) | (74.21) | (35.16) | — | |
Other operating activities |
12.34 | — | — | — | |
Operating Cash Flow |
(69.11) | (103.76) | (185.94) | — | |
Capital expenditures |
(0.89) | (1.99) | (1.64) | — | |
Change in intangibles (net) |
(1.02) | — | — | — | |
Short Term Investments Change (Net) |
69.67 | 54.80 | 4.50 | — | |
Other investing activities |
1.30 | 1.10 | 1.14 | — | |
Investing cash flow |
(57.18) | (15.66) | 3.57 | — | |
Repayment/Issuance of Debt (Net) |
44.59 | 19.14 | (5.36) | — | |
Equity Repurchase (Common, Net) |
29.25 | 0.15 | 1.79 | — | |
Financing cash flow |
73.84 | 19.29 | (3.57) | — | |
Exchange Rate Adjustment |
(0.40) | 0.57 | 0.00 | — | |
Change in Cash |
(52.85) | (99.56) | (185.94) | — | |
Beginning Cash |
143.99 | 90.18 | 90.18 | — | |
Ending Cash |
91.14 | (9.38) | (95.76) | — | |
Stock Based Compensation |
10.92 | 8.49 | 6.75 | — | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(70.91) | (102.61) | (82.98) | — | |
Investments Change (Net) |
69.67 | 54.80 | 4.50 | — | |
Issuance/Purchase of Shares |
29.25 | 0.15 | 1.79 | — |